A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

November 30, 2009

Conditions
Autistic DisorderAsperger SyndromeChild Development Disorders, Pervasive
Interventions
DRUG

N-acetylcysteine

Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.

DRUG

Placebo

Subjects randomized to placebo arm will receive placebo pill for duration of study.

Trial Locations (1)

46020

Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis

All Listed Sponsors
collaborator

National Alliance for Autism Research

OTHER

lead

Indiana University School of Medicine

OTHER

NCT00453180 - A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter